Extended-Interval Dosing With Zumilokibart May Redefine AD Management

Emerging data presented at the 2026 American Academy of Dermatology Annual Meeting suggest that extended-interval biologic therapy may meaningfully reshape treatment expectations in moderate to severe atopic dermatitis (AD). In an interview with Dermatology Times, Emma Guttman-Yassky, MD, PhD, discussed late-breaking results on zumilokibart (APG777; Apogee Therapeutics), highlighting a profile that combines durable efficacy with markedly reduced dosing frequency.

A central theme of the discussion was treatment burden. Patients with AD consistently express a preference for fewer injections, particularly when long-term disease control is required. Zumilokibart appears to address this concern, with clinical responses maintained and, in some cases, improved throughout 52 weeks despite infrequent administration. Patients received as few as 2 to 4 doses annually, a schedule that contrasts sharply with the every-2-week regimens commonly used with currently available biologics.

Beyond convenience, efficacy signals were notable. Guttman-Yassky emphasized that responses not only persisted from week 16 through week 52 but also deepened in some cases over time. The reporting of Eczema Area and Severity Index 100 responses (complete skin clearance) was particularly striking, as this level of response is not typically associated with biologic therapies in AD. Such outcomes, more commonly discussed in psoriasis using Psoriasis Area and Severity Index 100 benchmarks, may signal a shift in therapeutic goals for AD if replicated in larger data sets.

Speed of onset also remains a key consideration in treatment selection. According to Guttman-Yassky, rapid improvement paired with infrequent dosing positions zumilokibart as a potentially attractive first-line option for patients with moderate to severe disease, especially those seeking alternatives to frequent injections or oral therapies. Shared decision-making remains essential, but patient demand for less burdensome regimens is likely to influence prescribing patterns.

Safety findings were consistent with expectations for this therapeutic class. Conjunctivitis occurred in approximately 20% of patients, aligning with rates observed in prior long-term studies of established biologics. Most cases were mild to moderate, with few discontinuations and resolution achieved with or without treatment. The median onset at approximately 4 weeks suggests clinicians should remain vigilant early in the treatment course, particularly given the longer half-life associated with extended dosing intervals.

Looking ahead, Guttman-Yassky suggested that prolonged dosing strategies may become an important area of innovation across the AD treatment landscape. As newer agents demonstrate the feasibility of maintaining disease control with fewer administrations, future development may increasingly prioritize durability alongside efficacy and safety.

For clinicians, these findings underscore a potential paradigm shift—from simply achieving disease control to optimizing long-term management with therapies that better align with patient preferences and real-world adherence.